Presentations at the OIS- and Ora-sponsored Dry Horizons meeting
on May 3rd, at OIS
Retina on May 4th, and a
poster at ARVO
STUART,
Fla., April 19, 2024 /PRNewswire/ -- Stuart
Therapeutics, Inc., a clinical-stage ophthalmic biopharmaceutical
company focused on developing therapies for the treatment of
anterior segment, refractive and posterior segment eye disorders,
today announced that the company will be presenting its latest
research results at both the Association for Research in Vision and
Ophthalmology annual meeting, and at two meetings sponsored by the
Ophthalmology Innovation Source (OIS) in early May.
Eric Schlumpf, Stuart Therapeutics' President and CEO, will be
presenting at the Dry Horizons Symposium (co-sponsored by Ora,
Inc.) on Friday May 3rd.
His topic will be the company's innovative dry eye disease program,
currently in a Phase 3 trial. On Saturday,
May 4th he will be presenting the company's latest
pre-clinical results in retinitis pigmentosa and in exudative
retinal indications at the OIS Retina Meeting. Both of these
meetings will be held at the Four Seasons Hotel in Seattle, Washington.
Members of Stuart Therapeutics' R&D team also co-authored
a poster presentation that is being presented by researchers
from the University of Rochester at the
Association for Research in Vision and Ophthalmology (ARVO) Annual
Meeting, which will take place from May 5-9,
2024, in Seattle. The
poster presentation, entitled "Scleral collagen remodeling and
repair assessed in intact eyes through Second Harmonic Generation,"
covers work done at the University of
Rochester using Stuart Therapeutics' proprietary collagen
mimetic peptide platform to understand its efficacy in reversing
the disruption of scleral collagen in the eye, a likely source of
eye shape distortion in myopia. The study authors are Aldo
Tecse, Kaitlin Wozniak, James German, Alex
McMullen, Mark Buckley, Robert
Baratta, Eric Schlumpf,
Brian J. Del Buono, Michael Telias, and Susana Marcos.
About Stuart Therapeutics, Inc.
Stuart Therapeutics, founded in 2017 and based in Stuart, Florida, is the leader in the
development of ECM-targeting therapeutics for disease treatment.
Its platform technology, PolyCol™, is
a portfolio of synthesized collagen mimetic peptides designed to
specifically bind to and repair disease- or injury-damaged helical
collagen structures. This activity results in both a repair of
collagen structures and a restoration of homeostatic cell
signaling, with positive effects on cell growth and proliferation
and reduction in inflammation. These effects occur rapidly in
treated tissues, and Stuart Therapeutics has extensive research
results in a variety of refractive, anterior segment and posterior
segment ophthalmic disease indications. For more information,
visit www.stuarttherapeutics.com.
CONTACT: Eric Schlumpf,
President & CEO
eric@stuarttherapeutics.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/stuart-therapeutics-inc-announces-upcoming-presentations-at-arvo-2024-302122140.html
SOURCE Stuart Therapeutics